Phase 3 topline data expected 2Q25 for epetraborole in patients with treatment-refractory MAC lung disease (TR MAC) Phase 1 first
MENLO PARK, Calif. --(BUSINESS WIRE)--Mar. 3, 2025-- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing
AN2 Selects QOL-B as New Phase 3 Primary Efficacy Endpoint Goal to Accelerate Unblinding Phase 3 Data in Q2 2025
MENLO PARK, Calif. --(BUSINESS WIRE)--Feb. 20, 2025-- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing
MENLO PARK, Calif. --(BUSINESS WIRE)--Jan. 29, 2025-- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing
Founded in 2019, PTM Therapeutics is a San Francisco-based, pre-clinical stage startup that strives to “develop therapeutics for the betterment
Company announces Phase 2 part of the EBO-301 trial is now fully enrolled with 80 patients; Topline Phase 2 trial
Vaxcyte is set to raise $500 million via a stock sale to fund its work on a pneumococcal vaccine it
CAMBRIDGE, Mass., Sept. 20, 2022 /PRNewswire/ -- Octagon Therapeutics, a preclinical-stage biopharmaceutical company developing targeted medicines for autoimmune disease, today announced the